Browsing Viroloxía clínica by Author "Pernas, Berta"
Now showing items 1-15 of 15
-
Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?
Pernas, Berta; Grandal, Marta; Pértega-Díaz, Sonia; Cañizares, Angelina; Castro-Iglesias, Ángeles; Mena, Álvaro; Rodríguez-Osorio, Iria; Tabernilla, Andrés; Pedreira, José D.; Poveda, Eva (Oxford University Press, 2015-12-24)[Abstract] Objectives. The objective of this study was to evaluate the prevalence of blips and risk of virological failure (VF) among HIV-infected patients with sustained virological suppression (HIV-RNA <50 copies/mL) on ... -
Caracterización epidemiológica, clínica y virológica de los nuevos diagnósticos de infección por VHC en Galicia (2014-2015)
Pernas, Berta; Tabernilla, Andrés; Castro-Iglesias, Ángeles; Trigás, M.; Morano, L.; Mariño, A.; Rodríguez-Osorio, Iria; Ocampo, A.; Pereiro, C.; Poveda, Eva (Elsevier, 2016) -
Characterization of chronic HCV infection in Northwest Spain: impact of the treatment strategic plan of the Spanish National Health Service on HCV cure
Grandal, Marta; Pernas, Berta; Mariño, Ana; Álvarez, Hortensia; Tabernilla, Andrés; Castro-Iglesias, Ángeles; Mena, Álvaro; Delgado, Manuel; Pértega-Díaz, Sonia; Poveda, Eva (Wiley, 2017-03-14)[Abstract] The aim of the study was to characterize HCV infection in Northwest Spain and assess the impact of the Spanish Strategic Plan to cure HCV infection. Overall, 387 patients were included (60.9% HIV/HCV coinfected ... -
Clinical experience with the integrase inhibitors Dolutegravir and Elvitegravir in HIV-infected patients: efficacy, safety and tolerance
Cid-Silva, Purificación; Llibre, Josep M.; Fernández-Bargiela, Noelia; Margusino-Framiñán, Luis; Balboa-Barreiro, Vanesa; Pernas, Berta; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles; Poveda, Eva (Wiley, 2017-07-16)[Abstract] Two integrase inhibitors (INSTIs), dolutegravir (DTG) and elvitegravir/cobicistat (EVG/COBI), have joined recently the pharmacotherapy arsenal against HIV. This study evaluated the efficacy and tolerability of ... -
Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients: results in real clinical practice
Margusino-Framiñán, Luis; Cid-Silva, Purificación; Mena, Álvaro; Rodríguez-Osorio, Iria; Pernas, Berta; Delgado, Manuel; Pértega-Díaz, Sonia; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles (Sociedad Española de Quimioterapia, 2019)[Abstract] OBJECTIVE: Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients. The aim of this ... -
Impact of HCV infection in a HIV cohort followed over18 years: past and present
Mena, Álvaro; Rodríguez-Osorio, Iria; Meijide, Héctor; Castro-Iglesias, Ángeles; López-Calvo, Soledad; Vázquez Rodríguez, Pilar; Pernas, Berta; Grandal, Marta; Pedreira, José D. (Elsevier, 2015-04) -
Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin
Monje-Agudo, P.; Castro-Iglesias, Ángeles; Rivero-Juárez, A.; Martínez-Marcos, F.; Ortega-González, E.; Real, L.M.; Pernas, Berta; Merchante, N.; Cid-Silva, Purificación; Macías, J.; Merino, M.D.; Rivero, A.; Mena, Álvaro; Neukam, K.; Pineda, J.A. (Springer, 2015-07-09)[Abstract] It is commonly accepted that human immunodeficiency (HIV) coinfection negatively impacts on the rates of sustained virological response (SVR) to therapy with pegylated interferon plus ribavirin (PR). However, ... -
Increasing incidence of cancer in persons living with HIV coinfected with HCV: an additional impact of HCV infection?
Mena, Álvaro; Meijide, Héctor; Rodríguez-Osorio, Iria; Castro-Iglesias, Ángeles; Pértega-Díaz, Sonia; Rodríguez-Martínez, Guillermo; Pernas, Berta; Baliñas, Josefa; Pedreira, José D.; Poveda, Eva (Elsevier, 2016) -
Late HIV diagnosis but earlier antiretroviral treatment initiation in northwest Spain: impact of current treatment guidelines
Cid-Silva, Purificación; Margusino-Framiñán, Luis; Balboa-Barreiro, Vanesa; Pernas, Berta; Mena, Álvaro; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles; Poveda, Eva (Sage, 2019-01-10)[Abstract] Background: Current HIV treatment guidelines recommend antiretroviral treatment (ART) initiation for all HIV-infected individuals regardless of CD4 count. This study evaluates the immunological and virological ... -
Long-term clinical experience with darunavir (2007–2015) in a large cohort of HIV-infected patients in Spain authors
Pernas, Berta; Grandal, Marta; Tabernilla, Andrés; Cid-Silva, Purificación; Pértega-Díaz, Sonia; Castro-Iglesias, Ángeles; Mena, Álvaro; Margusino-Framiñán, Luis; Pedreira, José D.; Poveda, Eva (Wiley, 2016-06-06)[Abstract] The clinical experience with the protease inhibitor darunavir/ritonavir (DRV/r) was retrospectively evaluated in a cohort of 173 HIV+ patients who initiated antiretroviral treatment including DRV/r (period ... -
Molecular characterization of HIV-1 infection in Northwest Spain (2009–2013): investigation of the subtype F outbreak
Paraskevis, Dimitrios; Kostaki, Evangelia; Beloukas, Apostolos; Cañizares, Angelina; Aguilera, Antonio; Rodríguez, Javier; Grandal, Marta; Pernas, Berta; Castro-Iglesias, Ángeles; Mena, Álvaro; Pedreira, José D.; Poveda, Eva (Elsevier, 2014-12-16)[Abstract] Background. HIV-1 subtype B is the predominant one in European regions several, while other subtypes and recombinants are also circulating with high prevalence. A sub-epidemic of subtype F with specific ... -
Plasma mitochondrial DNA levels are inversely associated with HIV-RNA levels and directly with CD4 counts: potential role as a biomarker of HIV replication
Pernas, Berta; Rego-Pérez, Ignacio; Tabernilla, Andrés; Balboa-Barreiro, Vanesa; Relaño, Sara; Grandal, Marta; Crespo, Manuel; Mena, Álvaro; Castro-Iglesias, Ángeles; Blanco García, Francisco J; Poveda, Eva (Oxford, 2017-08-31)[Abstract] Objectives. To evaluate plasma mitochondrial DNA (mtDNA) levels among HIV-infected patients and its potential role as a biomarker of residual viral replication. Methods. HIV-infected patients on follow-up at a ... -
Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies
Grandal, Marta; Pernas, Berta; Tabernilla, Andrés; Mariño, Ana; Álvarez, Hortensia; Valcarce, Nieves; Mena, Álvaro; Castro-Iglesias, Ángeles; Pérez, Ana B.; Delgado, Manuel; Poveda, Eva (Wiley, 2018-02-10)[Abstract] The presence of resistance‐associated substitutions (RASs) at NS5A region might compromise the efficacy of Direct Acting Antiviral agents (DAAs). HCV resistance at NS5A region is mainly focused on patients with ... -
Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients
Rodríguez-Osorio, Iria; Cid-Silva, Purificación; Morano, Luis; Castro-Iglesias, Ángeles; Suárez, Marta; Delgado, Manuel; Margusino-Framiñán, Luis; Meijide, Héctor; Pernas, Berta; Tabernilla, Andrés; Pedreira, José D.; Mena, Álvaro; Poveda, Eva (Elsevier, 2017-01-18)[Abstract] Background. New direct-acting antivirals agents (DAAs) are very safe and well tolerated. Objectives. The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have ... -
Trends on epidemiological, virological, and clinical features among newly diagnosed HIV-1 persons in Northwest Spain over the last 10 years
Pernas, Berta; Mena, Álvaro; Cañizares, Angelina; Grandal, Marta; Castro-Iglesias, Ángeles; Pértega-Díaz, Sonia; Pedreira, José D.; Poveda, Eva (Wiley, 2015-03-16)[Abstract] To describe temporal trend and characteristics of newly HIV-diagnosed patients in a medical care area in Northwest Spain over the last 10 years. All newly diagnosed patients for HIV-infection from 2004 to 2013 ...
